English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Polycystic ovary syndrome (PCOS) is one of the most common causes of endocrinological disorders affecting 5-10% of women in reproductive age. It is the most important cause of anovulation and infertility. Objective: To examine the relation of body mass index in PCOS patients with dose and duration of Human Menopausal Gonadotropin (HMG), ovulation rate and pregnancy rate. Patients and Methods: The study was retrospectively conducted on 150 women selected from patients attending the infertility clinic of Al-Azhar hospitals, Faculty of Medicine, Al-Azhar University during the period from August 2018 till July 2020, and we revised and collected that data from the records. All cases were selected after fulfilling inclusion and exclusion criteria. The patients were divided into three equal groups according to their body mass index, Group A: patients with normal body mass index (BMI 19-24.9), Group B: patients with overweight (BMI 25-29.9) and group C: patients with obesity (BMI equals or more than 30). Results: There was a statistical significance as regards pregnancy rates between studied groups. In the current study there was a statistical significant difference between three groups as regards the mean age. There was no statistical significant difference between three groups as regards the mean Follicular Stimulating Hormone (FSH), Luteinizing Hormone (LH), Estradiol (E2), Prolactin (PRL) and Thyroid stimulating Hormone (TSH). According to the days of stimulation, group C showed a significant increase than group A and B. The dose of HMG used in the three studied groups, showed a significantly higher dose used in group C than group A and B. The ovulation rate was 68% in group A, 56% in group B and 28% in group C. The results were compared with other studies of similar scope and most of them were recent ones. In our study, obesity had negative impact on ovulatory functions. It seemed that obesity was a negative prognostic factor for women referred to vitro fertilization (IVF) treatment. They should be encouraged to change lifestyle habits in order to lose weight before starting fertility treatment. Although our findings did not support a policy of excluding obese and overweight women from IVF treatment on the grounds of likely failure of ovulation induction or IVF, Beyond the IVF results, obesity increased morbidity for both mother and fetus. There was an increased risk in pregnancy hypertension, toxemia, gestational diabetes, Cesarean section, increased hospitalization, and the risk to their offspring of their abnormality in BMI. Conclusion: Programs of weight loss are recommended for obese women undergoing in vitro fertilization, and the institution of a process of weight loss where appropriate, HMG can be given to patients with PCO adjusting dose according to their BMI and response with expecting satisfactory ovulation, and pregnancy rate.

BODY MASS INDEX IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME AND ITS RELATION TO DOSE AND DURATION OF HMG, OVULATION RATE AND PREGNANCY RATE